<DOC>
	<DOC>NCT00368186</DOC>
	<brief_summary>The primary objectives of this study were to assess the immunogenicity and the tolerance of the heptavalent pneumococcal conjugate vaccine (Prevenar) in young infants (2 months of age) with sickle cell disease when administred at 2,3, and 4 months of age.</brief_summary>
	<brief_title>Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.</brief_title>
	<detailed_description />
	<mesh_term>Anemia, Sickle Cell</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Inclusion Criteria Infants with neonatal diagnosis of sickle cell disease and confirmed hemoglobin status by hemoglobin electrophoresis. Exclusion Criteria Previous immunization with pneumococcalcontaining vaccines. History of pneumococcal invasive disease (meningitis, bacteremia, pneumonia). Known or suspected impairments of the immune system (including HIV infection) or recipients of immunosuppressant agents. Other Exclusions apply.</criteria>
	<gender>All</gender>
	<minimum_age>57 Days</minimum_age>
	<maximum_age>112 Days</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>